INT213

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.59
First Reported 1977
Last Reported 2010
Negated 1
Speculated 0
Reported most in Abstract
Documents 46
Total Number 46
Disease Relevance 19.78
Pain Relevance 16.79

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

transmembrane transport (AVP) cell-cell signaling (AVP) response to stress (AVP)
signal transducer activity (AVP) cytosol (AVP) extracellular space (AVP)
Anatomy Link Frequency
plasma 10
urine 4
MCN 4
cerebrospinal fluid 2
supraoptic nucleus 2
AVP (Homo sapiens)
Pain Link Frequency Relevance Heat
narcan 63 100.00 Very High Very High Very High
fluoxetine 33 100.00 Very High Very High Very High
opiate 33 100.00 Very High Very High Very High
Enkephalin 14 100.00 Very High Very High Very High
Nicotine 12 100.00 Very High Very High Very High
Clonidine 28 99.98 Very High Very High Very High
Endogenous opioid 22 99.98 Very High Very High Very High
Somatostatin 7 99.98 Very High Very High Very High
MU agonist 3 99.98 Very High Very High Very High
Dynorphin 3 99.92 Very High Very High Very High
Disease Link Frequency Relevance Heat
Syndrome 25 100.00 Very High Very High Very High
Hyponatremia 222 99.92 Very High Very High Very High
Nicotine Addiction 8 99.52 Very High Very High Very High
Cv General 3 Under Development 7 99.28 Very High Very High Very High
Hyperglycemia 2 98.94 Very High Very High Very High
Hypoglycemia 6 98.92 Very High Very High Very High
Overactive Bladder 52 98.76 Very High Very High Very High
Vomiting 53 98.72 Very High Very High Very High
Pressure Volume 2 Under Development 46 98.64 Very High Very High Very High
Weight Loss 1 98.56 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Naloxone decreases the inhibitory effect of ethanol on the release of arginine-vasopressin induced by physical exercise in man.
Negative_regulation (decreases) of Localization (release) of arginine-vasopressin associated with narcan
1) Confidence 0.59 Published 2009 Journal J Neural Transm Section Title Doc Link 19649691 Disease Relevance 0 Pain Relevance 0.42
When ethanol tests were repeated in the presence of naloxone, at both lower and higher dose, ethanol inhibition on AVP secretion was only partial, with mean peak responses 2.5 times higher than basal values.
Negative_regulation (inhibition) of Localization (secretion) of AVP associated with narcan
2) Confidence 0.59 Published 2009 Journal J Neural Transm Section Abstract Doc Link 19649691 Disease Relevance 0 Pain Relevance 0.40
In normal man, the centrally active alpha2-adrenoceptor agonist clonidine reduces arginine-vasopressin (AVP) secretion, probably by presynaptic inhibition of noradrenergic neuron terminals in the supraoptic nucleus.
Negative_regulation (reduces) of in neuron Localization (secretion) of AVP in supraoptic nucleus associated with agonist and clonidine
3) Confidence 0.59 Published 1999 Journal Clin. Auton. Res. Section Abstract Doc Link 10580879 Disease Relevance 0.43 Pain Relevance 0.50
Opiates appear to be involved in mechanisms which suppress the osmotically mediated release of vasopressin, while opiate involvement in baroceptor-mediated release may be quite different.
Negative_regulation (suppress) of Localization (release) of vasopressin associated with opiate
4) Confidence 0.57 Published 1980 Journal Lancet Section Abstract Doc Link 6107725 Disease Relevance 0.09 Pain Relevance 0.48
Inhibition of vasopressin release in man by an opiate peptide.
Negative_regulation (Inhibition) of Localization (release) of vasopressin associated with opiate
5) Confidence 0.57 Published 1980 Journal Lancet Section Title Doc Link 6107725 Disease Relevance 0.09 Pain Relevance 0.49
These results indicate that in humans FK 33-824 reduces AVP secretion and that this effect is not mediated by naloxone sensitive opiate receptors.
Negative_regulation (reduces) of Localization (secretion) of AVP associated with narcan and opiate
6) Confidence 0.57 Published 1980 Journal Acta Endocrinol. Section Abstract Doc Link 6252744 Disease Relevance 0 Pain Relevance 0.36
These results suggest that serotonergic pathways are not major regulators of the hypothalamic-pituitary-adrenal axis in humans or that FX has counteracting acute inhibitory effects on the axis, such as inhibition of hypothalamic arginine vasopressin secretion, which has been demonstrated in chronic animal studies.
Negative_regulation (inhibition) of Localization (secretion) of arginine vasopressin in pituitary associated with fluoxetine
7) Confidence 0.57 Published 1997 Journal Clin. Exp. Pharmacol. Physiol. Section Abstract Doc Link 9171947 Disease Relevance 0 Pain Relevance 0.95
Endogenous opioid mediation of somatostatin inhibition of arginine vasopressin release evoked by insulin-induced hypoglycemia in man.
Negative_regulation (inhibition) of Localization (release) of arginine vasopressin associated with hypoglycemia, somatostatin and endogenous opioid
8) Confidence 0.57 Published 1991 Journal J. Neural Transm. Gen. Sect. Section Title Doc Link 1673342 Disease Relevance 0.26 Pain Relevance 0.80
This difference may be due to a decline in the release of vasopressin during prolonged haemorrhage.
Negative_regulation (decline) of Localization (release) of vasopressin associated with cva
9) Confidence 0.56 Published 1991 Journal Dan Med Bull Section Abstract Doc Link 1802634 Disease Relevance 1.25 Pain Relevance 0.28
Kappa opioid agonists inhibit AVP release and offer new therapeutic possibilities and advantages over AVP peptides.
Negative_regulation (inhibit) of Localization (release) of AVP associated with mu agonist
10) Confidence 0.55 Published 1991 Journal J Clin Pharmacol Section Abstract Doc Link 1662231 Disease Relevance 1.09 Pain Relevance 0.47
Ethanol was the first agent recognized to inhibit ADH secretion.
Negative_regulation (inhibit) of Localization (secretion) of ADH
11) Confidence 0.54 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2504060 Disease Relevance 1.66 Pain Relevance 0.18
The first type of drugs blocks the tubular effect of antidiuretic hormone and the second inhibits antidiuretic hormone secretion by the neurohypophysis.
Negative_regulation (inhibits) of Localization (secretion) of antidiuretic hormone in neurohypophysis
12) Confidence 0.50 Published 2000 Journal J. Hepatol. Section Abstract Doc Link 10728802 Disease Relevance 1.05 Pain Relevance 0.14
Endogenous opioids inhibit oxytocin release during nicotine-stimulated secretion of vasopressin in man.
Negative_regulation (inhibit) of Localization (secretion) of vasopressin associated with nicotine and endogenous opioid
13) Confidence 0.50 Published 1988 Journal Clin. Endocrinol. (Oxf) Section Title Doc Link 3214943 Disease Relevance 0.39 Pain Relevance 0.75
Conversely, during conditions of hypotonicity, AVP secretion is suppressed, leading to excretion of dilute urine by the kidneys.2
Negative_regulation (suppressed) of Localization (secretion) of AVP in urine
14) Confidence 0.47 Published 2010 Journal Core evidence Section Body Doc Link PMC2899773 Disease Relevance 0.67 Pain Relevance 0.03
Naloxone decreases the inhibiting effect of ethanol on the release of arginine-vasopressin induced by cigarette smoking in man.
Negative_regulation (decreases) of Localization (release) of arginine-vasopressin associated with nicotine addiction and narcan
15) Confidence 0.43 Published 1987 Journal Metab. Clin. Exp. Section Title Doc Link 3600293 Disease Relevance 0.27 Pain Relevance 0.69
Effect of naloxone on the inhibitory effect of melatonin on the release of arginine-vasopressin induced by physical exercise in man.
Negative_regulation (effect) of Localization (release) of arginine-vasopressin associated with narcan
16) Confidence 0.43 Published 2010 Journal Regul. Pept. Section Title Doc Link 20346989 Disease Relevance 0 Pain Relevance 0.40
Oxilorphan suppressed urinary ADH excretion at the time of the osmotic threshold for ADH release in spite of the greater plasma osmolality.
Negative_regulation (suppressed) of Localization (release) of ADH in plasma
17) Confidence 0.43 Published 1980 Journal J. Clin. Endocrinol. Metab. Section Abstract Doc Link 6103008 Disease Relevance 0 Pain Relevance 0.50
Oxilorphan suppressed urinary ADH excretion at the time of the osmotic threshold for ADH release in spite of the greater plasma osmolality.
Negative_regulation (suppressed) of Localization (excretion) of ADH in plasma
18) Confidence 0.43 Published 1980 Journal J. Clin. Endocrinol. Metab. Section Abstract Doc Link 6103008 Disease Relevance 0 Pain Relevance 0.49
The data indicate that the narcotic antagonists are capable of inhibiting ADH release in man during ad libitum fluid intake and in response to an osmotic stimulus by elevating the osmotic threshold for ADH release.
Negative_regulation (inhibiting) of Localization (release) of ADH associated with antagonist
19) Confidence 0.43 Published 1980 Journal J. Clin. Endocrinol. Metab. Section Abstract Doc Link 6103008 Disease Relevance 0 Pain Relevance 0.51
However, peritoneal stimulations including open surgery cause both a systemic vasopressor response and a vasopressin release, which are suppressed by opiate administration.
Negative_regulation (suppressed) of Localization (release) of vasopressin associated with opiate
20) Confidence 0.43 Published 2001 Journal Acta Anaesthesiol Scand Section Abstract Doc Link 11308999 Disease Relevance 0.17 Pain Relevance 0.10

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox